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Apolipoprotein E polymorphism and renal disease. tribute to the progression of renal dysfunction [1–4].
Background. Lipid abnormalities are frequently found in However, few clinical studies in humans have addressed
end-stage renal disease (ESRD), and abnormal lipid metabo- the genetic pathogenesis of progressive renal insuffi-lism may contribute to the progression of renal disease. Previ-
ciency in relation to lipid abnormalities. Previous investi-ous investigators have reported that apolipoprotein E (apoE)
gators have reported that apolipoprotein E (apoE) hashas an important role in lipoprotein metabolism and that the
process of lipoprotein catabolism varies according to the apoE an important role in lipoprotein metabolism and that
phenotype. In addition, the relative frequency of the apoE the process of lipoprotein catabolism varies according
alleles is different among the races. In this study, we investi-
to the apoE phenotype [5, 6]. In this study, we investi-gated the allele frequency of apoE phenotypes and evaluated
gated the allele frequency of apoE phenotype and evalu-the impact of apoE polymorphism on lipid profile in Japanese
patients with renal disease. ated the impact of apoE polymorphism on lipid profile
Methods. ApoE phenotypes were determined using isoelec- in patients with renal disease.
tric focusing and Western blotting in 592 Japanese patients
with renal disease [86 out of 107 patients with glomerulonephri-
tis had proteinuria of not less than 0.25 g per 24 hr and 485 METHODS
with ESRD; 448 were on hemodialysis (HD), and 37 were on
ApoE phenotypes were determined using isoelectriccontinuous ambulatory peritoneal dialysis (CAPD)]. The allele
frequency and apoE phenotype distribution were estimated by focusing and Western blotting in 592 Japanese patients
the gene-counting method. Serum lipid parameters related to with renal disease [107 with glomerulonephritis and 485
lipid metabolism were measured after at least a 12-hour fast. with ESRD; 448 on hemodialysis (HD) and 37 on contin-Results. The allele frequency of the three major apoE phe-
uous ambulatory peritoneal dialysis (CAPD)]. Eighty-notypes (apoE2, apoE3, and apoE4) in 107 glomerulonephritis
patients (e2; 0.037, e3; 0.860, e4; 0.103) was almost identical to six of 107 patients with glomerulonephritis had protein-
that in the normal control population (e2; 0.036, e3; 0.848, e4; uria of not less than 0.25 g per 24 hours. ApoE phenotypes
0.115). However, 86 glomerulonephritis patients with protein- were determined using isoelectric focusing and Western
uria had higher allele frequency of apoE2 (e2; 0.052, P , 0.01)
blotting as described by Kataoka, Paidi and Howard [7].and apoE4 (e4; 0.140, P , 0.001) and lower allele frequency
We used the data reported by Davignon, Gregg andof apoE3 (e3; 0.808, P , 0.001) than the controls. Furthermore,
ESRD patients had higher allele frequency of apoE2 (e2; 0.058, Sing, and Eto, Watanabe and Ishii, who studied apoE
P , 0.01) and lower allele frequency of apoE4 (e4; 0.091, polymorphism in 440 and 576 Japanese individuals, re-
P , 0.05) than the controls. Higher prevalence of nephrotic spectively [8, 9]. The allele frequency and apoE pheno-syndrome was found in proteinuric glomerulonephritis patients
type distribution were estimated by the gene-countingwith apoE2. The impact of apoE polymorphism on serum lipid
method. Serum lipid parameters related to lipid metabo-profile in patients with glomerulonephritis, HD, and CAPD
was different from that generally expected. lism were measured in 107 patients with glomerulone-
Conclusions. The higher frequency of apoE2 in ESRD pa- phritis, 114 patients with HD, and 23 patients with CAPD
tients suggests that apoE2 is a possible genetic predisposition
after at least a 12-hour fast.to ESRD in a Japanese population. The impact of apoE2 and
apoE4 on lipid profile in patients with renal disease was unique
and different from that in the normal population.
RESULTS
The apoE phenotype of the 107 glomerulonephritis
Various lipid abnormalities have been found in pa- patients was E3/2 in 8 cases, E3/3 in 79 cases, E4/3 in 18
tients with renal disease, and hyperlipidemia may con- cases, and E4/4 in 2 cases. Allele frequency of apoE
phenotypes (e2; 0.037, e3; 0.860, e4; 0.103) was almost
identical to that of a Japanese control population [10].Key words: allele frequency, hyperlipidemia, glomerulonephritis, pro-
teinuria, dialysis. However, the patients with proteinuric glomerulonephri-
tis had a higher prevalence of apoE2 and apoE4 alleles, 1999 by the International Society of Nephrology
S-25
Oda et al: ApoE and renal diseaseS-26
Table 2. Differenes in the relative frequency of the commonTable 1. Allele frequency of apolipoprotein E phenotypes in
Japanese patients with proteinuric glomerulonephritis (GN), end- apolipoprotein E alleles among the races
stage renal disease (ESRD), and a normal Japanese population
N e2 e3 e4
GN patients ESRD patients Normal controlsa
American Indians 95 0.000 0.816 0.184(N 5 86) (N 5 485) (N 5 1,016)
Caucasians 5.805 0.080 0.769 0.150
USA (Framingham) 1,209 0.072 0.786 0.140e2 0.052b 0.058e 0.036
e3 0.808c 0.851 0.848 Germany 1,031 0.077 0.773 0.150
Canada (Ottawa) 102 0.078 0.770 0.152e4 0.140d 0.091f 0.115
Finland (Helsinki) 615 0.041 0.733 0.227gP , 0.001, x2 5 27.59 hP , 0.01, x2 5 10.55 Japanese 1,016 0.036 0.848 0.115
Chinese 196 0.084 0.852 0.064a Data for normal controls were obtained from the following studies on a
Japanese population: Davignon et al [8]; and Eto et al [9].
Data are from Davignon et al [8], and Eto et al [9].b P , 0.01 vs. Normal controls (x2 5 10.20)
c P , 0.001 vs. Normal controls (x2 5 26.78), d P , 0.001 vs. Normal controls
(x2 5 15.36), e P , 0.05 vs. Normal controls (x2 5 7.20), f P , 0.05 vs. Normal
controls (x2 5 10.55)
g Differences between GN patients and Normal controls
h Differences between ESRD patients and Normal controls DISCUSSION
Previous studies have reported that the prevalence of
type III hyperlipoproteinemia, dyslipoproteinemia or hy-
pertriglyceridemia as well as atherosclerosis is relativelyconsequently a lower apoE3/3 allele frequency, than the
lower in the Japanese population than the Caucasiancontrol population (Table 1). The apoE phenotype of
because of environmental factors such as dietary habitsthe ESRD patients was E2/2 in 1 case, E3/2 in 50 cases,
leading to lower plasma lipid levels or unknown geneticE3/3 in 347 cases, E4/2 in 4 cases, E4/3 in 82 cases,
factors [9]. Recently, the association between apoE2 alleleand E4/4 in 1 case. The allele frequency of apoE2 was
and low serum cholesterol levels and high triglyceride-significantly higher, and that of apoE4 was significantly
rich lipoprotein levels, as well as the association betweenlower in the ESRD patients than those in the control
apoE4 allele and high serum levels of cholesterol andpopulation.
triglycerides, has been reported [11]. Moreover, allele
Lipid profile showed the proteinuric patients with
frequencies of apoE2 and apoE4 are significantly lower,
apoE2 phenotype had significantly higher levels of uri-
and that of apoE3 allele is significantly higher in the
nary protein excretion rate per 24 hours, blood urea Japanese population than those in the Caucasian (Table
nitrogen, serum creatinine and triglycerides (247 6 143 2) [8, 9], indicating a lower prevalence of atherosclerosis
mg/dl), and showed an accumulation of intermediate and nephrosclerosis in the Japanese population.
density lipoprotein than those with apoE3/3 and apoE4 Horita et al reported the association between apoE2
phenotypes, whereas the serum total cholesterol level in and renal insufficiency in Japanese non-insulin-depen-
patients with the apoE2 phenotype (263 6 117 mg/dl) dent diabetes mellitus patients [12]. In this study, we
was not lower than those in patients with apoE3/3 (215 6 found a higher prevalence of the apoE2 allele in our
54 mg/dl) and apoE4 phenotypes (244 6 124 mg/dl). patients with ESRD than in a Japanese population, sug-
Moreover, the proteinuric patients with the apoE4 phe- gesting that apoE may contribute to the progression of
notype had a significantly lower level of serum creatinine, renal disease associated with impaired lipid metabolism.
as well as a higher creatinine clearance value, whereas Feussner et al studied the apoE polymorphism in 560
the serum levels of total cholesterol and triglycerides German HD patients and concluded that there was no
(165 6 154 mg/dl) were identical to those in patients association between apoE2 allele and ESRD, indicating
with apoE3/3 phenotype (triglycerides, 152 6 76 mg/dl). the apoE2 allele frequency of ESRD (e2; 0.084) and that
We have previously reported a characteristic lipid profile of the German controls (e2; 0.077) [13]. The discrepancy
of the HD and CAPD patients [10]. Briefly, the HD between Feussner’s study and ours may be attributed to
patients with apoE4 had a significantly higher serum the differences in the race [9]. One study from Spain
triglyceride level than those with apoE3/3. The serum also concluded that there was no association between
total cholesterol level in the HD patients with apoE2 apoE polymorphism and ESRD; however, because the
was not lower than those with apoE3/3 and apoE4, sample size in their study is small (202 cases each for
whereas the percentage of serum low density lipoprotein HD and controls), further study may be required. An-
against the whole serum lipoproteins in the HD patients other group from Boston also reported no association
with apoE2 was significantly lower. The CAPD patients between apoE genotypes and the development of early
with apoE2 had significantly lower total and low density or advanced diabetic nephropathy in patients with insu-
lipoprotein cholesterol levels than those with apoE4. lin-dependent diabetes mellitus [14]. However, the num-
However, the triglyceride level in CAPD patients with bers of the subjects are also small (patients with normo-
albuminuria in 74 cases, microalbuminuria in 31 cases,apoE2 was not higher than those with apoE3 and apoE4.
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